Rome said the results highlight the role of eRT in modulating the immune response, supporting its potential as a therapeutic target for autoimmune disease.
The data will be presented TODAY at the American College of Rheumatology Convergence 2021 Virtual Meeting. ROME has identified eRT as its first target and will continue to advance this program to identify eRT inhibitors for further development.
Approximately 60% of the human genome consists of repetitive sequences of nucleic acids, known as repeats.
Certain repeats, such as LINE1 and HERV-K, encode functional eRTs. These eRTs convert RNA into DNA in the cytosol, triggering nucleic acid-sensors, such as cGAS, leading to a viral mimicry response characterized by production of Type I interferon.
Because excess Type I interferon production can lead to autoimmune disease, eRT inhibitors, which block the reverse transcription of repeat RNA into DNA, have the potential to improve pathological outcomes.
The data show that a potent and selective eRT inhibitor, Compound A, demonstrated the following:
- Inhibition of LINE1 retrotransposition in a cellular assay
- Inhibition of Type I interferon response in a cellular model of Aicardi-Goutières Syndrome
- Attenuation of antigen-specific T cell responses in MOG-immunized mice
Rome Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome vast stretches of uncharted genetic material that have long been dismissed as the "dark genome."
With several drug targets identified and multiple discovery programs underway, Rome is moving rapidly to leverage this new frontier in biology.
To lead this exploration, Rome has assembled a team of professionals across fields including oncology, immunology, virology, chemistry and machine learning. Rome is based in Cambridge, Mass.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Innovent Biologics announces CFO transition
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial